These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 22009255)
1. Application of plasma lipidomics in studying the response of patients with essential hypertension to antihypertensive drug therapy. Hu C; Kong H; Qu F; Li Y; Yu Z; Gao P; Peng S; Xu G Mol Biosyst; 2011 Dec; 7(12):3271-9. PubMed ID: 22009255 [TBL] [Abstract][Full Text] [Related]
2. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. Middeke M; Richter WO; Schwandt P; Holzgreve H Int J Clin Pharmacol Ther; 1997 Jun; 35(6):231-4. PubMed ID: 9208337 [TBL] [Abstract][Full Text] [Related]
3. Weight reduction versus antihypertensive drug therapy in obese men with high blood pressure: effects upon plasma insulin levels and association with changes in blood pressure and serum lipids. Fagerberg B; Berglund A; Andersson OK; Berglund G J Hypertens; 1992 Sep; 10(9):1053-61. PubMed ID: 1328365 [TBL] [Abstract][Full Text] [Related]
4. Antihypertensive treatment, high triglycerides, and low high-density lipoprotein cholesterol and risk of ischemic heart disease mortality: a 16-year follow-up in the Copenhagen male study. Suadicani P; Hein HO; Gyntelberg F Metab Syndr Relat Disord; 2010 Jun; 8(3):215-22. PubMed ID: 20156073 [TBL] [Abstract][Full Text] [Related]
5. Antihypertensive treatment alters the predictive strength of pulse pressure and other blood pressure measures. Greenberg J Am J Hypertens; 2005 Aug; 18(8):1033-9. PubMed ID: 16109316 [TBL] [Abstract][Full Text] [Related]
6. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Yilmaz MI; Sonmez A; Caglar K; Celik T; Yenicesu M; Eyileten T; Acikel C; Oguz Y; Yavuz I; Vural A Nephrology (Carlton); 2007 Apr; 12(2):147-53. PubMed ID: 17371337 [TBL] [Abstract][Full Text] [Related]
7. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Hermida RC; Ayala DE; Mojón A; Fernández JR Chronobiol Int; 2010 Sep; 27(8):1629-51. PubMed ID: 20854139 [TBL] [Abstract][Full Text] [Related]
8. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment]. Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399 [TBL] [Abstract][Full Text] [Related]
9. Blood lipid changes in hypertensive, dyslipidemic patients under long term quinapril treatment. Cangelosi MM; Gaudio M; Brancati AM; Leggio F Int Angiol; 1994 Mar; 13(1):65-7. PubMed ID: 8077801 [TBL] [Abstract][Full Text] [Related]
10. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973 [TBL] [Abstract][Full Text] [Related]
11. Effect of antihypertensive therapy on serum lipids in newly diagnosed essential hypertensive men. Nandeesha H; Pavithran P; Madanmohan T Angiology; 2009; 60(2):217-20. PubMed ID: 18445617 [TBL] [Abstract][Full Text] [Related]
13. Long-term effect of antihypertensive therapy with calcium antagonist or angiotensin converting enzyme inhibitor on serum nitrite/nitrate levels in human essential hypertension. Takase H; Sugiyama M; Nakazawa A; Sato K; Ueda R; Dohi Y Arzneimittelforschung; 2000 Jun; 50(6):530-4. PubMed ID: 10918945 [TBL] [Abstract][Full Text] [Related]
14. Effect of antihypertensive treatment on the increased beta 2-adrenoceptor density in patients with essential hypertension. Bono M; Cases A; Calls J; Gaya J; Jiménez W; Carretero J; Rivera F; Revert L Am J Hypertens; 1995 May; 8(5 Pt 1):487-93. PubMed ID: 7662225 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk factors are not treated to target in hypertensive patients in primary care. Nieburg I; Kahan T Blood Press; 2010 Jun; 19(3):176-81. PubMed ID: 20429693 [TBL] [Abstract][Full Text] [Related]
16. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). Hobbs FD; Gensini G; Mancini GB; Manolis AJ; Bauer B; Böhler S; Genest J; Feldman R; Harvey P; Jenssen TG; Metcalfe M; da Silva PM; Int J Cardiol; 2006 Jun; 110(2):242-50. PubMed ID: 16338012 [TBL] [Abstract][Full Text] [Related]
17. The therapeutic importance of home blood pressure assessment and combination antihypertensive therapy for achieving target blood pressure control: Ibaraki hypertension assessment trial. Sato A; Watanabe S; Okubo S; Toi T; Doi T; Nakano H; Tada J; Aonuma K; Hypertens Res; 2010 Dec; 33(12):1264-71. PubMed ID: 20927115 [TBL] [Abstract][Full Text] [Related]
18. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C; Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142 [TBL] [Abstract][Full Text] [Related]